News

The gift will be used to treat and potentially cure eye diseases such as macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal protein buildup in the stromal layer of the cornea.

Mark Daly discusses the transformative role of AI in ophthalmology, highlighting its potential to enhance patient care and streamline physician workflows.

Brazilian regulatory authority ANVISA grants marketing authorization for Ranivisio.

Jay Chhablani, MD, explains how 3D choroidal vessel segmentation transforms ophthalmology, enhancing disease diagnosis and treatment through advanced imaging technology.

The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future treatments.

Catch up on this week's highlights in retina.

On the heels of the drug's FDA approval, clinicians weigh in on acoltremon’s (Tryptyr) novel mechanism of action and its potential to address unmet needs in dry eye care

The ELEVATUM study explored faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities, showcasing significant visual acuity improvements.

Research findings from the multicentre clinical study were presented at the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal

Special programming for young ophthalmologists will be hosted in the YO lounge

This year’s multi-specialty programme features the SOE Leadership Development Programme (EuLDP), the International Society of Ocular Trauma (ISOT), European University Professors of Ophthalmology (EUPO) and more

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

Researchers share that perfluorohexyloctane eye drops offer rapid relief for dry eye disease, enhancing patient comfort before cataract surgery.

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease connections using advanced OCT technology.

The preservative-free, contact lens–friendly drops have been formulated to provide hydration and comfort for dry eyes in a multidose bottle.

A study reveals attrition rates in patients with geographic atrophy on complement inhibitor therapies, highlighting the need for improved treatment adherence strategies.

Centennial Optical distributes ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories.

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, offering reduced risks and improved outcomes.

Gore recently launched its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes for the delivery of ophthalmic drugs.

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).

The 0.1 mg/ml atropine eye drop for paediatric myopia is licensed from Sydnexis, Inc.

Areas covered by the agreement would cover key Asian marketplaces, including Japan and China.

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025.